IJUP08 - Universidade do Porto
IJUP08 - Universidade do Porto
IJUP08 - Universidade do Porto
- TAGS
- universidade
- porto
- ijup.up.pt
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Calcium uptake by rat hippocampal synaptosomes: regulation by<br />
en<strong>do</strong>genous adenosine and different depolarizing agents<br />
A. Rocha, M.G.B. Lobo, and P. Correia-de-Sá<br />
Laboratório de Farmacologia e Neurobiologia, UMIB, Instituto de Ciências Biomédicas Abel<br />
Salazar, <strong>Universidade</strong> <strong>do</strong> <strong>Porto</strong>, Portugal.<br />
Adenosine is an en<strong>do</strong>genous modulator of the CNS refraining neuronal excitability (e.g. [1]).<br />
Because en<strong>do</strong>genous levels of adenosine rise markedly during seizure activity, this nucleoside has<br />
been proposed as an “en<strong>do</strong>genous anticonvulsant”. The anticonvulsant effect of adenosine may be<br />
due to A receptors activation [2] leading to suppression of voltage-dependent Ca<br />
1 2+<br />
entry [3].<br />
Animal models and human tissue (from epileptics submitted to neurosurgery) exhibit similar<br />
mechanisms underlying epileptic disorders [4]. Synaptosomes – isolated nerve endings that<br />
maintain physiological properties such as the ability to release neurotransmitters in a Ca 2+<br />
-<br />
dependent manner - are throughly used to study pathogenesis of epilepsy. Veratridine (VT, a<br />
selective Na +<br />
opener), 4-aminopyridine (4-AP, a nonselective K +<br />
channel blocker) and high K +<br />
concentrations are the most common strategies to depolarise synaptosomal plasma membrane as<br />
they allow to differentiate between presynaptic Na +<br />
channel-mediated responses; these compounds<br />
increase intracellular Ca 2+<br />
accumulation in the rat hippocampus as well as in the human brain.<br />
Nevertheless, we recently showed that the choice of depolarising agent (VT vs high [K +<br />
]) may be<br />
crucial for evidencing para<strong>do</strong>xical effects of drugs regulating Ca 2+<br />
influx into hippocampal<br />
synaptosomes, such as nifedipine [5]. Therefore, we investigated whether the same occurred using<br />
4-AP as compared with VT. We also tested the modulatory role of en<strong>do</strong>genous adenosine on<br />
neuronal Ca 2+<br />
uptake by incubating hippocampal synaptosomes with adenosine deaminase (ADA),<br />
which inactivates adenosine into inosine.<br />
Synaptosomes were prepared from rat hippocampal homogenates [5]. Samples (50 μl) of<br />
synaptosomal suspension were pre-incubated with test drugs for 10 min, at 37 ºC. Synaptosomal<br />
loading was performed during 3 min with 45<br />
CaCl (0.32 μCi/μmol) in the presence of the<br />
2<br />
depolarizing agent. Adding ice-cold Tris-EGTA solution followed by filtration under negative<br />
pressure through GF/C glass fibre filters, terminated 45<br />
Ca uptake. The radioactivity associated with<br />
the synaptosomes was determined by liquid scintillation spectrometry.<br />
Inactivation of en<strong>do</strong>genous adenosine with ADA (0.5 UmL -1<br />
) caused a global increase on 45<br />
Ca<br />
uptake into the rat hippocampal synaptosomes, indicating that there is a significant adenosine<br />
inhibitory tonus regulating depolarisation-induced Ca 2+<br />
influx into nerve terminals. VT (5 μM)<br />
increased 45<br />
Ca uptake into hippocampal synaptosomes (67±9 %, n=4). 4-AP (10 mM) increased<br />
45<br />
Ca uptake to a lesser extent (23±4%, n=4). Co-application of VT (5 μM) together with 4-AP (10<br />
mM) increased 45<br />
Ca uptake (138±15 % (n=4) above the control level. This higher-than-additive<br />
effect, contrasts with the additive result obtained upon applying VT (1-10 μM) together with high<br />
[K +<br />
] (15-30 mM) [5], indicating the existence of synergism between VT and 4-AP.<br />
[1] Cunha, R. Neurochem. Int. 38, 107-125, 2001<br />
[2] Zhang, G., Franklin, P.H. & Murray, Eur. J. Pharmacol.,255, 239-243,1994<br />
[3] Wu, L.G. & Sagau, P, Neuron, 12, 1139-1148, 1997<br />
[4] Avoli,M., Louvel,J., Pumain,R. & Kohling,R., Prog. Neurobiol., 22, 166-200, 2005<br />
[5] Costa, J. Lobo, M.G.B. & Correia-de-Sá., Eur. J. Pharmacol., 544, 39-48, 2006<br />
103